The aging risk factor for Parkinson's disease is described in terms of specific disease markers including mitochondrial and gene dysfunctions relevant to energy metabolism. This review details evidence for the ability of nutritional agents to manage these aging risk factors. The combination of alpha lipoic acid, acetyl-L-carnitine, coenzyme Q10, and melatonin supports energy metabolism via carbohydrate and fatty acid utilization, assists electron transport and adenosine triphosphate synthesis, counters oxidative and nitrosative stress, and raises defenses against protein misfolding, inflammatory stimuli, iron, and other endogenous or xenobiotic toxins. These effects are supported by gene expression via the antioxidant response element (ARE; Keap/Nrf2 pathway), and by peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC-1 alpha), a transcription coactivator, which regulates gene expression for energy metabolism and mitochondrial biogenesis, and maintains the structural integrity of mitochondria. The effectiveness and synergies of the combination against disease risks are discussed in relation to gene action, dopamine cell loss, and the accumulation and spread of pathology via misfolded alpha-synuclein. In addition there are potential synergies to support a neurorestorative role via glial derived neurotrophic factor expression.
Introduction
Progress is needed to improve outcomes for patients with Parkinson's disease (PD) . Treatments aimed at correcting the characteristic dopaminergic deficits, although they are effective in controling symptoms, fail to prevent progression of the underlying disease. The aging process is the greatest risk factor for the development and progression of the typical (sporadic) form of the disease (PD) (Collier et al., 2011; Hindle, 2010) . It thus seems logical to ask whether agents known to directly influence aspects of the aging process, can play a role in the management of this risk for PD.
Many reviews have examined the role of mitochondrial dysfunction, oxidative stress and energy production in aging, and PD (e.g., Cassarino and Bennett, 1999; Hauser and Hastings, 2013; Henchcliffe and Beal, 2008; Martin, 2010; Nicholls and Budd, 2000; Olanow, 1993; Shigenaga et al., 1994) . Although not fully understood, there is a reduction in the efficiency of the mitochondrial electron transport chain (ETC) and adenosine triphosphate (ATP) production with age, associated with leakage of electrons and an excess production of superoxide anions, leading potentially to the production of further reactive oxygen radicals via Fenton chemistry, and to the formation of damaging nitrogen species (Beckman, 1994; Halliwell, 1992; Harman, 1956) . Mitochondrial enzymes of the Krebs tricarboxylic acid (TCA) cycle, the protein complexes of the ETC, the lipid cristae which embed these complexes and mitochondrial DNA are thus all at a high risk of damage in the course of aging. In aging and in PD, underexpression of genes associated with energy metabolism, compounds these adverse events in mitochondria. Moreover this change of gene expression is a feature of the preclinical stage of PD (Zheng et al., 2010) . When endogenous defenses can no longer resist these stresses, neuropathologic changes may accumulate, notably in dopamine neurons, which are rendered especially susceptible to the combined effects of energy deficit and oxidative stress by the catechol structure and metabolism of dopamine (Cohen, 1994; Kristal et al., 2001; Lamensdorf et al., 2000; Marchitti et al., 2007) .
Abnormalities in PD also occur outside the central dopaminergic pathways, as there is evidence of widespread dysfunction (shown by biochemical change, gene underexpression, pathology, and functional deficit) in other non-dopamine central neurons, autonomic and sensory pathways, and peripheral structures including nonneural tissue (Beach et al., 2010; Braak et al., 2003; Gibson et al., 2003; Halliday, 2009; Hargreaves et al., 2008; Harris et al., 1992; Hindle, 2010; Jain et al., 2011; Jellinger, 1999; Mytilineou et al.,1994; Zheng et al., 2010) , and many patients later develop cortical pathology (Braak et al., 2003) and dementia (Hindle, 2010) .
Some of the changes in the central nervous system associated with PD are also found, in less severe form, in normal aging tissue. Thus, the reduction in dopamine, complex I, reduced glutathione, alpha ketoglutarate dehydrogenase, and the increase in markers for oxidative stress, alpha synuclein, amyloid, iron and mitochondrial DNA deletions, which are found in PD, also occur in the course of normal aging (Bender et al., 2006; Braidy et al., 2011; Carretero et al., 2009; Chu and Kordower, 2007; Collier et al., 2011; Darbin, 2012; Hauser and Hastings, 2013; Hindle, 2010; Long et al., 2009a) , the latter including a reduction of the antioxidant defense signal nuclear factor (erythroid-derived 2)-like2 (Nrf2) (Suh et al., 2004; Tufekci et al., 2011) , and the transcription regulator for energy metabolism, peroxisome proliferatoractivated receptor gamma co-activator 1 alpha (PGC-1alpha) (Jiang et al., 2013) , as well as ATP and nicotinamide adenine dinucleoide (NADþ) (Braidy et al., 2011; Jiang et al., 2013) .
This selective review discusses evidence for specific properties of alpha lipoic acid, acetyl-L-carnitine, coenzyme Q10, and melatonin, which can manage these age related risks relevant to PD. In practice, case history evidence shows that, when used in combination, they appear effective in restraining progression (Phillipson, 2013) . This result indicates that support of mitochondrial function and gene expression by these agents, may be sufficient to significantly reduce the impact of some aging risk factors for PD.
R-alpha-lipoic acid

Role in energy metabolism
The extraction of energy from carbohydrate sources proceeds via metabolism to pyruvate, followed by transport across the mitochondrial inner membrane to the matrix, and conversion to acetyl coenzyme A (acetylCoA) by the giant multienzyme complex pyruvate dehydrogenase (PDH). The reaction requires thiamine pyrophosphate, lipoic acid, NADþ, and coenzyme A. In mammalian species PDH may consist of more than 100 enzyme molecules, comprising 20e30 pyruvate decarboxylase units, 60 lipoate transacetylase and 20e30 lipoate dehydrogenase units (enzymes E1, E2, and E3, respectively). As each E2 covalently binds 2 lipoate molecules, the whole complex requires 120 molecules of lipoic acid for optimal function. Overall the reaction yields carbon dioxide, nicotinamide adenine dinucleotide (NADH) and acetylCoA. AcetylCoA provides a common end stage intermediate of metabolism for both carbohydrates and beta oxidation of fatty acids and enters the TCA cycle for further processing via citrate and isocitrate to alpha-ketoglutarate. The conversion of alphaketoglutarate to succinylCoA by alpha-ketoglutarate dehydrogenase (KGDH) is considered rate limiting for the whole cycle. KGDH is a giant multienzyme complex with many similarities to PDH, converting NADþ to NADH, yielding carbon dioxide, consuming coenzyme A and requiring lipoic acid (Zubay, 1998) .
Influence of aging and PD
Both PDH and KGDH are sensitive to inhibition by free radical production arising from peroxidation of membrane lipids, which is associated with the aging process in mitochondria (Long et al., 2009b; reviewed in Packer and Cadenas, 2011) . A major aldehyde product of lipid peroxidation is 4-hydroxy-2-nonenal (HNE).
In vitro testing of purified PDH and KGDH shows that HNE inhibits both enzymes by targeting covalently bound lipoate on E2 (Humphries and Szweda, 1998) . Moreover, thiols, including lipoic acid, provide protection against HNE-induced inactivation of lipoyl-containing complexes in mitochondria (Korotchkina et al., 2001 ). Glutathione, the major cellular thiol antioxidant, present in millimolar concentrations, is also able to protect KGDH against H 2 O 2 and HNE toxicity by forming reversible disulphide adducts with lipoic acid (Applegate et al., 2008) . Oxidative stress and lipid peroxidation thus pose a threat to energy production via the inhibition of PDH and KGDH.
Basal levels of HNE are reported as <1mM and subtoxic concentrations between 0.5 and 5.0 mM (Petersen and Doorn, 2004) .
HNE is normally removed by glutathione conjugation and is the major disposal route. Increased oxidation of reduced glutathione in the early stages of PD (Sian et al., 1994) , suggests that there is an increased risk to key TCA cycle enzymes by HNE-induced inhibition. Since it requires 25e50 mM HNE to substantially inhibit purified PDH and KGDH in vitro (Humphries and Szweda, 1998) , it seems that a more than 10-fold increase in HNE is needed to inhibit NADH production by the cycle. A reported 10-fold increase in "cholesterol-lipid hydroperoxides" in PD brain , suggests that this degree of oxidative stress may be sufficient to cause significant PDH and KGDH inhibition in vivo. In addition, a 6-fold increase in the presence of HNE-bound proteins in the substantia nigra has been reported in patients who died with PD (Yoritaka et al., 1996) . Furthermore, an immunohistochemical study of KGDH in PD found reduced staining in substantia nigra especially in the lateral one third, correlating roughly with severity of degeneration (Mizuno et al., 1994) . In brain areas not affected by neurodegeneration, another study revealed that KGDH activity in the cerebellum is reduced by 50% in PD. Because the enzyme proteins appeared normal, it was suggested that reactivation of the protein, presumably with cofactors, may be useful (Gibson et al., 2003) . These results suggest that there is a widespread KGDH deficit in PD which is not secondary to degenerative change, but which may result in part from an increase in oxidative stress associated with progression of disease. More evidence of a widespread state of oxidative stress in PD is noted in the following sections. Procedures aimed at raising glutathione and lipoic acid levels to relieve inhibition of PDH and KGDH may thus facilitate the supply of NADH and succinate to feed the ETC, via complex I and II respectively, thereby supporting mitochondrial respiration (Humphries and Szweda, 1998) .
Experimental studies
Lipoic acid is a direct and indirect antioxidant. In vitro it is able to scavenge a variety of reactive oxygen species including superoxide, nitric oxide, peroxynitrite and the hydroxyl anion, and can regenerate vitamins C and E (Packer, 1994) . Furthermore, it is able to chelate a variety of transitional metals including Fe3þ and Cu2þ, which may play a role in the continuation of neurodegeneration by promoting oxidative stress (Suh et al., 2005; Youdim and Lavie, 1994) .
However, perhaps a key property of lipoate is the ability to act as an indirect antioxidant via the antioxidant response element (ARE). This involves induction of phase II antioxidants via the Keap1/Nrf2/ARE pathway, which controls the expression of more than 200 genes, including those required for reduced glutathione (GSH) synthesis (Kwak et al., 2003; Shay et al., 2009; Suh et al., 2004) . The regulation of GSH involves glutamate cysteine ligase, glutathione synthase, glutathione S-transferase, glutathione peroxidase, and reductase, all of which respond to Nrf2 control of gene expression. Lipoic acid would thus seem well suited to provide support to counter the GSH deficit in PD and inhibition of PDH and KGDH by the products of lipid peroxidation. Furthermore, the induction of aldehyde dehydrogenase (ALDH), which also occurs on Nrf2 activation (Calkins et al., 2009) , may promote metabolism of HNE.
In vitro testing of a variety of cell lines including astroglia and neuroblastoma, has confirmed that lipoic acid can restore GSH in GSH depleted cells, and also protect complex I inhibition induced by GSH depletion (Bharat et al., 2002; Flier et al., 2002; Han et al., 1997) . This latter effect is significant in view of the reduction in the activity of complex I in PD (Schapira et al., 1990) .
In vivo, lipoic acid decreases the level of lipid peroxidation, increases GSH, and enhances the activities of several mitochondrial enzymes including KGDH, succinate dehydrogenase (complex II), and NADH dehydrogenase (complex I) in aged animals (Arivazhagan et al., 2001; Jiang et al., 2013) . Reduction of the intracellular concentration of GSH can also lead to persistent inhibition of complex I and inhibition of cellular respiration in the presence of nitric oxide (NO). GSH protects the enzyme either by preventing nitrosylation of critical thiols or by removing NO from nitrosylated sites (Clementi et al., 1998; Moncada and Bolanos, 2006) . Lipoic acid may thus not only improve the supply of substrate to complex I via PDH and KGDH, but protect complex I in cooperation with GSH.
Two other significant responses to the induction of the Nrf2/ARE pathway by lipoic acid are the increased expression of NAD(P)H, quinone oxoreductase (NQO1), and ferritin. NQO1 will be discussed in more detail later, together with coenzyme Q, with which it appears to cooperate to assist in electron transport and control oxidative stress. Ferritin is an intracellular iron binding protein, which sequesters free iron and can thus prevent Fenton chemistry from exacerbating oxidative stress. Furthermore, Nrf2 dependent induction of catalase, thioredoxin reductase, and superoxide dismutase (Calkins et al., 2009 ) adds significantly to neuroprotective defenses.
Additional potentially beneficial responses are induction of several genes involved in the conversion of glucose to pyruvate, the expression of isocitrate dehydrogenase and pyruvate dehydrogenase (facilitating energy production), induction of dopa decarboxylase (facilitating dopamine synthesis), nitric oxide synthase inhibitor proteins, chaperone and proteosome proteins (involved in the recognition, repair, and removal of damaged proteins), and reduction of inflammatory signals (Calkins et al., 2009; Kwak et al., 2003; Suh et al., 2004) . Energy metabolism may be further influenced by lipoic acid, via an increase in ATP synthesis (Zimmer et al., 1991) , and via an insulin-like effect, increasing glucose uptake in neural tissue of aging rats (Jiang et al., 2013) .
It seems that Nrf2-associated responses occur primarily in astrocytes, indicating that glial-neuronal cross talk is largely responsible for these neuroprotective properties (Calkins et al., 2009) . However, neuronal cultures lacking astrocytes can also display Nrf2 dependent protection against toxic stimuli (Tufekci et al., 2011) .
The evidence suggesting a possible neuroprotective role for Nrf2 signals, has been tested directly in various mouse models of experimental parkinsonism in which Nrf2 deficient mice show reduced resistance to 6-hydroxydopamine, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP), and alpha-synuclein toxicity (Jakel et al., 2007; Jazwa et al., 2011; Lastres-Becker et al., 2012) , while activation of the Nrf2 pathway by triterpenoids attenuates MPTP neurotoxicity (Kaidery et al., 2013) . This has given rise to the notion that Nrf2 responses might provide neuroprotection to patients with PD (reviewed in Tufekci et al., 2011) . The occurrence of strong nuclear localization of Nrf2 in the surviving substantia nigra neurons in PD suggests a failing attempt to provide such protection and counter oxidative stress (Ramsey et al., 2007) .
Combination of lipoic acid with other nutrients, such as acetyl-Lcarnitine and coenzyme Q has been proposed as providing additional benefits (Liu, 2008) .
Acetyl-L-carnitine
Role in energy metabolism
It is often assumed that glucose is the main source of energy in the brain. However, the contribution from the oxidation of long chain fatty acids should not be ignored especially in conditions of relative starvation and during the night (Aureli et al., 1990) . Fatty acid oxidation yields large amounts of ATP. For example, the complete oxidation of 1 molecule of palmitoyl-CoA yields 108 moles ATP, whereas 1 molecule of glucose yields 30 (a ratio of 7:5 ATP per carbon atom, respectively). The acetyl-CoA derived from fatty acids can penetrate the outer membrane of mitochondria, but is unable to cross the inner membrane. To gain access to the matrix it must first be converted to a carnitine derivative. This is achieved by carnitine acting as an acyl-shuttle between carnitine acyltransferase I in the outer membrane, and carnitine acyltransferase II plus a carrier protein on the inner membrane, yielding free carnitine for recycling, while the acyl-CoA generated in the matrix enters beta oxidation. The end product of this process, which yields NADH and FADH2, is acetyl-CoA, which then enters the TCA cycle for further metabolism (Zubay, 1998) . This mechanism, together with the age related loss of serum and mitochondrial carnitine, provides a rationale for countering some of the effects of aging on mitochondrial respiration with acetyl-L-carnitine (ALC) (reviewed by Shigenaga et al., 1994) .
ALC treatment appears to shift cerebral energy metabolism away from glucose utilization toward glycogen synthesis (Aureli et al., 1998) and to favor processing of citric acid cycle intermediates via increase in the activity of the rate limiting KGDH in cerebral synaptic mitochondria (Gorini et al., 1998) . In view of the earlier discussion, this effect may be of benefit in PD.
Effects on aging
Feeding old rats with ALC is able to counter age related decline in tissue carnitine levels and improve fatty acid utilisation, but because this increases electron flow through the ETC, it may also produce an increase in oxidative stress (Hagen et al., 1998) . This problem is circumvented by coupling ALC with the antioxidant lipoic acid (LA). In vivo, the combination of ALC þ LA results in partial reversal of age related decline in the mitochondrial membrane potential, and oxygen consumption, thus facilitating oxidative phosphorylation. Further benefits are restoration of the age related decrease in cardiolipin (a phospholipid cofactor for protein complexes in the ETC), restoration of age related changes in ascorbate and GSH, enhancement of glucose uptake, reduced formation of lipid peroxidation products malondialdehyde (MDA) and HNE, and reduction of the age related accumulation of iron and copper (Hagen et al., 2002) . These findings obtained in hepatocytes, have been extended to brain mitochondria and cortical tissue with similar results (Long et al., 2009a; Suh et al., 2005) , including normalization of GSH, superoxide dismutase, and protein carbonyl formation. However, the reduction in complex I in old rats, is only partially restored. Futhermore, the affinities of complex I for cofactor coenzyme Q and substrate NADH, which are lowered in old rats (an increase in Km), are unchanged by ALC þ LA.
These biochemical findings have been complemented by electron microscopic studies of the brains of aged rats treated with ALC þ LA (Aliev et al., 2009) . While old control rats show half the percentage of intact mitochondria compared with young controls, treatment of old rats with ALC þ LA restores the numbers to young control levels. Furthermore, the number of completely destroyed mitochondria in old rats is halved by treatment.
Thus, the effect of ALC þ LA treatment in vivo appears to significantly hinder or reverse several factors underlying the vicious cycle of age-related mitochondrial decay and hence cellular dysfunction.
Effects in models of PD
ALC alone appears to be effective in primate models, providing some, albeit weak protection against MPTP induced parkinsonism (Bodis- Wollner et al., 1991) . Studies of in vitro cell lines exposed to a variety of mitochondrial inhibitors and uncoupling agents show that both L-carnitine and ALC attenuate cell damage (Virmani et al., 1995) .
Using an in vitro model of PD in which neuroblastoma cells are exposed to the complex I inhibitor rotenone, pretreatment with a combination of ALC þ LA protects against the inhibitor induced loss of complex I, and reduction of mitochondrial membrane potential, ATP, and GSH; and also reduces the level of protein and DNA oxidation, accumulation of alpha-synuclein, ubiquitin, and reactive oxygen species. In the absence of rotenone ALC þ LA increases the number of viable mitochondria and mitochondrial DNA expression, apparently via induction of the signaling molecule PGC-1alpha; a regulator of the transcription factor for mitochondrial biogenesis and respiration. The combination exhibits strong synergy as the agents together show 100e1000-fold greater potency in several tests (including the PGC-1alpha assay) when compared with individual use (Zhang et al., 2010) .
A variety of experimental techniques show that PGC-1alpha provides potent protection in vivo and in vitro against reactive oxygen species, alpha-synuclein, rotenone, and MPTP induced neurodegeneration (Mudo et al., 2012; St-Pierre et al., 2006; Wareski et al., 2009; Zheng et al., 2010) .
Significantly, genome-wide meta-analysis of gene sets, indicates that those sets involved in mitochondrial biogenesis and energy metabolism, many of which respond to PGC-1alpha, appear to be underactive in patients with PD compared with age matched controls (Zheng et al., 2010) .
Other gene functions
Additional influences on gene transcription relevant to neuroprotection by ALC have been reported. Treatment of cultured astrocytes with ALC induces heme oxygenase-1 (HO-1), heat shock protein 60, and the redox sensor Nrf2, as well as antiinflammatory signals (Calabrese et al., 2005) . In vivo treatment with ALC induces the gamma isoform of 14-3-3 protein and heat shock protein 72 in rat brain (Traina et al., 2004) . HO1 is a rate limiting enzyme for the production of the potent antioxidant bilirubin from heme and iron. Heat shock proteins are chaperones which protect against damage by misfolded proteins, and gamma 14-3-3 is one of a family of 14-3-3 proteins acting as chaperones to a very wide variety of proteins and nucleic acids. These responses might thus contribute to a strategy to improve outcomes in PD via protection from the risk of macromolecular oxidation and misfolding during aging.
Effects on neurotransmission
ALC has a variety of effects on neurotransmission (Jones et al., 2010) . Significantly, ALC has beneficial effects on the dopaminergic system of the aging brain. The 50% loss of D1 dopamine receptor activity with age is reduced by prior ALC treatment, while the electrically evoked stimulation of dopamine release from aged striatal tissue is enhanced by in vivo pretreatment with ALC (Sershen et al., 1991) . Additional effects influence functional aspects of 5HT, noradrenergic, cholinergic, and gamma-aminobutyric acid neurons (Imperato et al., 1989; Jones et al., 2010; Smeland et al., 2012; Tempesta et al., 1985) . The integrated effect of these actions is as yet unclear, but the cholinergic responses may have a role to play in reversing the age related decline in cholinergic function and acetylcholine synthesis, and may influence the pontine cholinergic cell loss in PD (Pahapill and Lozano, 2000) . Pontine cholinergic neurons make direct excitatory synaptic connection to the cell bodies of the nigro-striatal dopaminergic pathway (see Bolton et al., 1993) .
Membrane functions
Many of the neuronal responses described previously may result, not only from ALC acting via improved energy supply, and gene activity, but also by acting more directly to provide acetyl moieties to be used, for example in acetylcholine synthesis, or by providing activated acyl groups for the acylation of membrane phospholipids (Jones et al., 2010) . These latter effects can markedly affect membrane fluidity and influence charge characteristics of phospholipids, proteins, receptors, ion channels, uptake sites, and membrane bound enzymes. Such effects may underlie the beneficial action of ALC on mitochondrial membranes, cardiolipin, and the embedded complexes of the ETC (Shigenaga et al., 1994) .
Coenzyme Q
Coenzyme Q (CoQ; ubiquinone) has a well established role as a vital component of the ETC in the inner mitochondrial membrane, where it undergoes redox cycling (the Q cycle) between complexes I (NADH ubiquinone oxoreductase), II, and III. In the process it indirectly supports the export of protons to maintain the membrane potential across the inner membrane. This potential is essential for ATP synthesis, which is dependent on reverse proton chemiosmosis.
Coenzyme Q is also present outside mitochondria, and in reduced form (ubiquinol) acts as an antioxidant in all tissues, protecting cell membrane lipids, phospholipids, proteins, and nucleic acids from free radical damage (Ernster and Dallner, 1995) .
CoQ and complex I in PD
CoQ10 deficiency has been reported in peripheral tissues from patients with PD, including those with early untreated disease (Mischley et al., 2012; Schults et al., 1997) . Furthermore, there is a highly significant fall in the ratio of reduced to oxidized CoQ (Sohmiya et al., 2004) , suggesting a systemic state of oxidative stress. In the central nervous system marked loss of CoQ has been reported in the cerebral cortex, but not in substantia nigra, striatum or cerebellum in PD (Hargreaves et al., 2008) ; interpreted as reflecting cortical oxidative stress and consistent with change to other oxidative stress markers found in cerebral cortex in PD (Dalfo et al., 2005; Radunovic et al., 1997) . These results should be considered in the context of a normal age related decline of CoQ in brain and other tissues (Spindler et al., 2009) .
The transfer of electrons through the iron-sulfur complexes of complex I involve the reduction of CoQ. The changes in CoQ found in PD might thus result in part from the inhibition of complex I activity in PD, which occurs not only in substantia nigra (Mann et al., 1992; Schapira et al., 1990) , but also in cerebral cortex and many peripheral tissues (Parker et al., 2008) . The origin of the complex I defect is at present unknown, but is consistent with a generalized state of oxidative stress, which in turn occurs as part of the normal process of aging (Long et al., 2009a) . For example, oxidized nitrogen species can irreversibly inhibit complex I in the presence of low GSH (Clementi et al., 1998; Moncada and Bolanos, 2006) . Other possibilities include oxidative damage to membrane phospholipids and/or mitochondrial DNA, and xenobiotic chemical complex 1 inhibitors (Cleeter et al., 1992) .
Taken along with evidence cited earlier for reduction in the provision of NADH from the TCA cycle to fuel complex I and II activity, these factors, together with underexpression of genes associated with energy metabolism, contribute to impairments in PD which threatens cellular integrity. Clearly the contribution of normal aging to specific processes associated with PD should not be ignored when considering supportive management. Furthermore, the widespread nature of oxidative stress and energy impairment in PD is consistent with findings of neuropathologic changes in brain areas outside dopaminergic pathways (Halliday, 2009; Jellinger, 1999 ) not only centrally, but also in peripheral tissues (e.g. Drolet et al., 2009 ).
Experimental and clinical studies
In vitro cell culture studies have shown that CoQ protects against the complex I inhibitors MPPþ and rotenone (Fontaine et al., 1998; Gille et al., 2004; Moon et al., 2005) as well as the oxidative stress induced by paraquat, H 2 O 2 and transitional metals (Kooncumchoo et al., 2006; McCarthy et al., 2004; Somajajulu et al., 2005) . Furthermore, CoQ can inhibit inflammatory responses, acting via gene signaling (Kooncumchoo et al., 2006; Schmelzer et al., 2008) .
In animal models, feeding CoQ is effective in raising brain mitochondrial CoQ levels (Matthews et al., 1998) , but the protection offered by CoQ against the MPTP model of PD is only partial.
Against this background the clinical experience of CoQ monotherapy in PD has yielded conflicting results (Spindler et al., 2009 ) and a recent phase III trial has shown that CoQ, although safe, is ineffective in the long term (Clinical trials. gov, 2011).
CoQ and LA cooperation
Because the reduced form of CoQ (ubiquinol) needs to be continually regenerated to sustain the Q cycle operating between complexes I-III, and given the presence of a complex I deficiency in PD, additional mechanisms to support recycling appear to be needed. Such a mechanism appears possible by combining CoQ with LA.
As noted previously, Nrf2 signals induced by LA results in the expression of the antioxidant enzymes NQO1 and thioredoxin reductase. Both of these enzymes appear able to reduce oxidized CoQ to ubiquinol in the cytosol using extramitochondrial nicotinamide adenine dinucleotide phosphate (NADPH) and NADH equally well (Beyer et al., 1996; Xia et al., 2003) . Reduced CoQ can then enter the mitochondrial membrane to react with complex III, providing protons for export and electrons for the ETC. This also allows for an electron bypass to compensate for complex I insufficiency.
Reducing equivalents may also be transferred from cytosolic NADH to CoQ in the mitochondrial membrane via the glycerol-3-phosphate shuttle (McKenna et al., 2006) , but it is unknown whether this route is enhanced as a result of Nrf2 signals.
NQO1 is especially useful to dopamine neurons, as it protects the catechol moiety of dopamine from oxidation and so reduces the consequent formation of further reactive oxygen species (ROS). Furthermore, NQO1 induced by LA confers resistance to peroxynitrite, H 2 O 2 and 4HNE toxicity in a catecholamine cell line in vitro (Jia et al., 2008) . It may also control proteosomal degradation of damaged or aggregated proteins (Dinkova-Kostova and Talalay, 2010).
Taken together, the evidence suggests a potentially powerful cooperative effect of combining CoQ and LA to provide neuroprotection, especially to dopamine neurons in PD, using gene expression evoked by Nrf2.
Melatonin
A substantial body of evidence exists (reviewed by Escames et al., 2010) to suggest that some of the adverse risks associated with the aging process and PD, including the reduction in melatonin secretion with age, loss of GSH, complex I and antioxidant control, may be managed by melatonin replacement.
Antioxidant defenses and mitochondrial functions
Numerous studies indicate that melatonin plays an important role in antioxidant function and mitochondrial homeostasis. Melatonin can gain access to all subcellular compartments with ease, and while unequally distributed within the cell, it may accumulate to levels of 100 nM in nuclei and mitochondria (Editorial, 2003) . Many studies, however, used doses of melatonin well in excess of what can be considered physiological.
Melatonin and some metabolites are excellent scavengers of reactive oxygen and nitrogen species (Galano, 2011; Tan et al., 2007) . Following in vivo injection, melatonin increases the messenger RNA (mRNA) for glutathione peroxidase, copper-zinc superoxide, and manganese superoxide dismutase in rat brain cortex. Interestingly, smaller doses result in larger effects (Kotler et al., 1998) . These enzymes form part of cellular defenses against free radicals formed from H 2 O 2 , iron, NO, and superoxide. In vitro experiments using neuronal cell lines have confirmed that physiological serum concentrations of melatonin produce large increases in mRNA for both dismutases and glutathione peroxidase (Mayo et al., 2002) . Mitochondria do not contain catalase and are thus largely dependent on GSH for antioxidant protection against H 2 O 2 . Melatonin at 100 nM is able to restore GSH in isolated GSH-depleted brain mitochondria, and increases glutathione peroxidase and reductase activities . The reductase acts to regenerate GSH from the oxidized disulphide using NADPH as cofactor. Because GSH synthesis occurs mainly in glial cells, the neuroprotection afforded by GSH is effected by glianeuronal cross talk. Melatonin at 100 nM protects the viability of astrocytes against 200 mM H 2 O 2 and produces a large increase in mRNA for glutathione peroxidase induced by H 2 O 2 (Martin et al., 2002a) .
In addition to improving antioxidant defenses, melatonin increases the activity of enzyme complexes of the ETC, and the production of ATP. In sub-mitochondrial particles, melatonin at physiological concentrations (10e100 nM) increases the activity of complex I and IV and the amount of ATP (Martin et al., 2002b) . In isolated liver mitochondria, melatonin at physiological concentrations protects against oxidative damage by reducing oxygen consumption and the membrane potential, thus reducing superoxide and H 2 O 2 production, while simultaneously maintaining the efficiency of oxidative phosphorylation and ATP synthesis by increasing mainly complex I and IV activity . In senescence accelerated mice there are significant age associated decreases in complex I and IV and glutathione peroxidase activities which are counteracted by daily melatonin in the drinking fluid (Okatani et al., 2002) . The response of complex IV to melatonin is greater than that of complex I, a result in agreement with the in vitro findings Martin et al., 2000) . Melatonin has also been proposed as a significant factor in the protection of these complexes by preventing the peroxidation of cardiolipin (Paradies et al., 2010) .
Additional benefits of melatonin for the functioning of the ETC arise from the ability to preserve the nicotinamide nucleotides NADPH and NADH. Preservation of NADPH promotes the activity of glutathione reductase, thus maintaining GSH. Under conditions of oxidative stress the interaction of superoxide with NADH generates an NAD radical, setting up a vicious cycle of reactions leading to reduced NADH levels. Melatonin can recycle the NAD radical to NADH (Tan et al., 2005) thus preserving NADH as substrate for complex I, facilitating ATP production.
Role of nitric oxide
While the hydroxyl radical is often considered to be the main toxic species produced in oxidative stress, via Fenton chemistry, the high reactivity limits the extent of diffusion. Furthermore, rate constants for synthesis are low, and endogenous defenses should normally quench radical formation effectively. By contrast, the formation of the powerful oxidant peroxynitrite (ONOO -) from NO and superoxide proceeds a million times faster than the Fenton reaction, and ONOO -diffusion exceeds that of the hydroxyl radical by a factor of 10,000. ONOO -efficiently oxidizes -SH groups, lipids, proteins, and DNA. It can also produce stable nitration of protein tyrosine residues, which may significantly disrupt phosphorylation reactions needed for signal transduction (Beckman, 1994) . It has been noted previously (see section 2.3) that NO can persistently inhibit complex I in the presence of low GSH. Furthermore, in cultured dopaminergic neuronal cell lines, NO, and ONOO -induce irreversible damage to complex I, tyrosine nitration of complex I subunits, impaired mitochondrial respiration, reduction in ATP synthesis and apoptotic cell death (Antunes et al., 2002; Yamamoto et al., 2002) . Because NO can give rise to a wide variety of reactive nitrogen species (RNS), additional sources of complex I inhibition are possible, and may include S-nitration, release of iron, damage and disassembly of Fe-S clusters, modification of NADH, ubiquinone or flavins, and oxidation of phospholipids (Brown and Borutaite, 2004) . Against this background, it is highly significant that the enzyme responsible for generating NO, nitric oxide synthase (NOS), is inhibited by melatonin at physiological concentrations (1 nM) in striatum (Leon et al., 1998) cerebellum and hypothalamus (see Reiter et al., 1998) . Kinetic analysis of the purified neuronal enzyme shows the inhibition to be non competitive, calcium/ calmodulin-dependent and that some kynurenine metabolites may show even greater activity (Leon et al., , 2006 . In vivo inhibition of NOS by 7-nitroindazole or melatonin (at high dose) or a melatonin metabolite prevents complex I inhibition, tyrosine nitration, and dopamine depletion produced in MPTP treated mice (Schulz et al., 1995; Tapias et al., 2009) .
The ability of melatonin to control the production of both ROS and RNS by increasing dismutase and other antioxidant enzymes, as well as via NOS inhibition, means that melatonin acts as a powerful indirect antioxidant even at physiological concentrations. Control of NOS may be especially significant because the rate constant for ONOO -formation from NO and superoxide is three times faster than that for removal of superoxide by dismutase (Beckman, 1994) . It is well documented that aging is associated with marked reductions in the nocturnal secretion of melatonin (Escames et al., 2010) . According to the evidence cited, this factor may account for some of the oxidative and nitrosative damage risk occurring in the aging process and in PD, specifically by failure of adequate protection of mitochondria, including complex I and GSH.
Melatonin and glial derived neurotrophic factor
In addition to the neuroprotective actions of melatonin described previously, a neurorestorative role appears possible via the ability to influence glial derived neurotrophic factor (GDNF). Following the original purification and cloning of this factor (Lin et al., 1993) , it has become apparent that GDNF has the potential to reverse the continuing degeneration of dopamine neurons in PD. However, technical problems have so far hampered progress in both the experimental and clinical arena (Allen et al., 2013; Kirik et al., 2004) . Alternatively, it may become possible to stimulate regeneration given an understanding of the signaling pathways controlling GDNF expression (Saavedra et al., 2008) . In this respect, melatonin or melatonin receptor agonists may prove useful.
Physiological doses of melatonin provide neuroprotection against unilateral 6-hydroxydopamine induced rotation and loss of tyrosine hydroxylase activity in an animal model of hemiparkinsonism ) associated with complex changes in GDNF. In vitro rat C6 glioma cell lines, which express both G protein coupled melatonin MT1 and MT2 receptor subtypes, melatonin (0.1e100 nM) produces a dose dependent increase in GDNF mRNA expression suggesting that MT1 receptor mediated GDNF secretion might be beneficial in PD (Armstrong and Niles, 2002) . The neural stem cell line C17.2 similarly responds to melatonin with enhanced GDNF mRNA expression (Niles et al. 2004) .
Both MT1 and MT2 receptors are negatively coupled to the adenyl cyclase cyclic adenosine monophosphate pathway. Activation by melatonin leads to suppression of cyclic adenosine monophosphate and decrease in protein kinase A (PKA) and protein phosphorylation, with resulting change in transcription factors and gene expression via the Raf, MAPK/ERK pathway and hence activity of specificity protein 1 and activating protein 2 (Masana and Dubocovich, 2001 ). Both specificity protein 1 and activating protein 2 binding sites are present in the GDNF promoter, providing nuclear receptors for information regulating GDNF transcription (Baecker et al., 1999; Suter-Crazzolara and Unsicker, 1996; Verity et al., 1998; Witt-Enderby et al., 2000; Woodbury et al., 1998) . Protein kinase A regulates the phosphorylation of cyclic adenosine monophosphate response element binding protein, a factor which also controls GDNF and brain-derived neurotrophic factor (BDNF) expression via a binding site in the promoter region (Baecker et al., 1999; Woodbury et al., 1998) .
Melatonin regulates GDNF also via a second G(q/11) protein pathway which mobilizes Caþþ. Activation of membrane bound phospholipase C by Caþþ releases further Caþþ from intracellular stores via inositol triphosphate to activate GDNF transcription. Phospholipase C also increases diacyl glycerol which stimulates phosphokinase C (PKC) (Armstrong and Niles, 2002; Brydon et al., 1999; Verity et al., 1998) . Melatonin can also stimulate purified PKC directly (Anton-Tay et al., 1998; Hunt et al., 2001) . In cultures of human derived astrocytes, PKC inhibitors dramatically reduce GDNF mRNA expression (Moretto et al., 1996) , and stimulation of PKC raises GDNF production in C6 cells (Verity et al., 1998) .
Tyrosine hydroxylase (the rate limiting enzyme for dopamine synthesis) is induced by melatonin, acting probably via the MAPK/ ERK pathway (McMillan et al., 2007) , i.e., in common with one route used by melatonin for GDNF expression.
Discussion
Efforts to manage dysfunctional mitochondria in PD have thus far proved ineffective (Swerdlow, 2009) , since no single agent has the range of effects required to address multiple adverse processes and gene activities. Here, the properties of four agents have been analyzed to show that, together, they appear to provide the necessary protection against known risks of the aging process with respect to PD. The combination of LA, ALC, CoQ, and nocturnal melatonin can improve defenses against oxidative and nitrosative stress, enhance energy metabolism via carbohydrate and fatty acid utilization, assist mitochondrial electron transport and ATP synthesis, and promote defenses against protein misfolding, inflammatory stimuli, iron, and other endogenous or xenobiotic toxins. These properties allow disease risk factors, outlined in the introduction, which are common to both aging and PD to be addressed. Case history evidence that these aging risks associated with PD can be managed effectively by this combination to inhibit progression (Phillipson, 2013) is consistent with the observed association of aging as the major risk factor for the sporadic form of PD.
Many of the properties of this combination are associated with, and may result from, changes to gene regulation, for example via increased expression of the antioxidant response element (ARE; Keap/Nrf2/ARE pathway) as outlined previously, and the induction of PGC-1alpha; the latter resulting in stimulation of mitochondrial biogenesis and improved mitochondrial morphology. In addition, PGC-1alpha and Nrf2 interact mutually and induce nuclear respiratory factor 1, which activates mitochondrial transcription factor A (Tfam), a protein regulator of mitochondrial DNA transcription, translation, and repair (see Tufekci et al., 2011) thus providing protection against age-related mitochondrial DNA damage. Underexpression of PGC-1alpha responsive genes has been found in PD compared with age-matched controls (Zheng et al., 2010) . These include gene "sets" which are associated with pyruvate metabolism, the TCA cycle, electron transport, oxidative phosphorylation and other mitochondrial, and glucose sensing genes. Furthermore, these gene sets appear underexpressed, not only in dopamine, but also in non-dopamine and extraneural tissues in PD, as well as in preclinical incidental Lewy body disease. Taken together, this evidence suggests that widely distributed abnormalities in energy metabolism are associated with the origins and development of PD, and that this plays some part in explaining the effectiveness of this combination of supplements in counteracting progression, specifically via the synergistic ability of LA and ALC to induce PGC-1alpha (Zhang et al., 2010) . However, it should be emphasized that this action via gene expression for both the ARE pathway and PGC-1alpha, appears, by itself, insufficient to counter disease risks in PD (Phillipson, 2013) , and that CoQ is also required, presumably to support the Q cycle for electron transport between complexes IeIII, and help circumvent complex I inhibition in cooperation with Nrf2 signaling as described previously. Additional nocturnal support of antioxidant defense is provided by melatonin.
The sensitivity of catecholamine neurons to conditions of oxidative stress, and the protective properties of glutathione to the catechol moiety of dopamine are well known (Cohen, 1994) . Glutathione also protects against the oxidative properties of H 2 O 2 normally produced during the metabolism of dopamine via monoamine oxidase (MAO). Conditions of low glutathione in aging and in PD thus increase risks of oxidative and nitrosative damage to dopamine neurons, which can be addressed by Nrf2 signaling and melatonin as described previously. Similar protection is provided against the agerelated increase in glial MAO-B, which poses risks to KGDH and complex I activity via increased H 2 O 2 production (Kumar et al., 2003) .
The metabolism of dopamine to dihydroxyphenylacetaldehyde (DOPAL) via MAO-A, presents additional risks to dopamine neurons during aging. Normally DOPAL is rapidly converted to inert metabolites, mainly via ALDH, but in raised concentration DOPAL is toxic to dopamine neurons producing stable protein adducts and cross-linking (reviewed in Marchitti et al., 2007) . Aging produces profound reduction in the essential ALDH cofactor NADþ (Braidy et al., 2011) , and increased production of lipid peroxidation products MDA and HNE. These in turn inhibit ALDH activity and are capable of increasing DOPAL levels by 5e10-fold. In addition, DOPAL can inhibit ALDH via protein adduction, even though it is the normal substrate. In spite of these risks, however, complete inhibition of DOPAL metabolism producing a 5e6-fold increase in DOPAL does not produce toxicity in cultured PC12 cells with a healthy metabolism. Only when there is accompanying metabolic and mitochondrial stress does DOPAL toxicity become apparent (Kristal et al., 2001; Lamensdorf et al., 2000) . These observations directly demonstrate the crucial importance of mitochondrial functions in the protection of dopamine neurons and explain at least in part the special liability of these neurons to undergo degenerative change in aging and especially in PD. A similar process applies to noradrenergic neurons which also degenerate in PD.
In the context of the present article, the support of mitochondrial function as described seems well suited to reduce these risks of catecholamine oxidation and DOPAL toxicity, since Nrf2 and PGC1alpha signaling increase both glutathione and ALDH, reduces lipid peroxidation and hence MDA and HNE, and aids a variety of mitochondrial functions including support of gene expression for energy metabolism. Further neuroprotection may be provided via control of toxic alpha-synuclein oligomers and aggregates, which may arise as a result of the reaction between DOPAL and alphasynuclein (Burke et al., 2008) .
The protein alpha-synuclein appears to play an important role in PD pathogenesis, as it forms the major component of Lewy bodies (LB) and neurites, found in both dopamine and nondopamine neurons. Normal aging is associated with marked increase in alpha-synuclein in the substantia nigra in humans, but this is in a diffuse and soluble form, and is not localized in LB form as it is in PD (Chu and Kordower, 2007) . However, reactive oxygen species can result in alpha-synuclein aggregation, and the LB contains oxidized and nitrated forms of alpha-synuclein (Giasson et al., 2000) . Such misfolding and accumulation risks the loss of one physiological function of alpha-synuclein, namely regulation of mitochondrial Caþþ uptake from the endoplasmic reticulum (Cali et al., 2012) with consequent disruption of Caþþ homeostasis. Furthermore, misfolded alpha-synuclein impairs complex I, ATP synthesis, and the mitochondrial membrane potential, producing further oxidative stress, microglial activation and neuroinflammation (Chinta et al., 2010; Devi et al., 2008; Dunning et al., 2013) . The significance of these events for pathogenesis of age related PD is illustrated by alpha-synuclein gene mutations, which are associated with the rare autosomal dominant form of PD (see Dunning et al., 2013) .
Protection against these events may be achieved by the combination of LA þ ALC, which reduces the accumulation of alpha-synuclein (Zhang et al., 2010) , and activates antioxidant Nrf2 signals. These may reduce protein misfolding produced by oxidative stress, and reduce the aggregates generated by protein cross-linking in the presence of DOPAL by enhancing DOPAL metabolism via ALDH. Additional protection may be afforded by melatonin, which prevents oligomerization and all stages of fibril formation in alpha-synuclein resulting in reduced neuronal cytotoxicity (Ono et al., 2012) . These properties may thus also play a role in the ability of this combination to counter disease progression (Phillipson, 2013) , since misfolded alpha-synuclein apears to be involved in the spreading of PD pathology (Braak et al., 2003; Dunning et al., 2013) .
Melatonin, in addition to its antioxidant properties, may also have the potential to support a neurorestorative role. The melatonin MT1 receptor is present in human brain in all major dopaminergic regions (Uz et al., 2005) . However, it remains to be determined whether melatonin retains the capacity to support GDNF expression via MT1 activity, given that melatonin receptors are reduced in PD (Adi et al., 2010) . Furthermore, the complexity of intracellular signals following melatonin receptor stimulation (see section 5.3) suggests that the outcome with respect to GDNF is likely to depend on other factors. For example, activity via Nrf2 stimulation of HO-1 expression may be significant (Surh et al. 2009 ), as HO-1 has the potential to increase both GDNF and BDNF and their mRNA scripts in substantia nigra (Hung et al., 2008 (Hung et al., , 2010 . Furthermore, since PKC is proposed as an upstream activator of both Nrf2 (Giudice et al. 2010; Tufecki et al., 2011) and GDNF, activation of PKC by melatonin as described (see section 5.3) may amplify this Nrf2/HO-1/GDNF signal pathway. It remains to be determined whether this allows for synergy to operate between LA þ ALC driven Nrf responses and melatonin in respect of GDNF. Additional potential synergy between melatonin and CoQ10 via the phosphatidylinositide 3-kinase (PI3K) pathway (Choi et al., 2012; Kong et al., 2008 ) also requires investigation as to GDNF production. Furthermore, since HO-1 mediated GDNF expression also appears to utilize PI3K (Hung et al., 2010) , LA, ALC, CoQ10, and melatonin may all have a role to play in the regulation of GDNF.
Safety
The nutrients discussed in this article have all been used for decades in a variety of clinical situations. Thus so far they do not appear to have raised serious safety issues, and they seem to be well tolerated, and appear to lack significant side effects or signs of toxicity as revealed in laboratory tests (Clinical Trials.gov. 2011; Cremer et al., 2006; de Grandis et al., 2002; Lemoine et al., 2011; Seabra et al., 2000; Shay et al., 2009; Spindler et al., 2009 ). The doses required to control the aging risk factor in the PD case history described (Phillipson, 2013) , are less than those used in these long term studies. In particular, for melatonin, a method of physiological nocturnal administration is employed (Lemoine et al., 2011) .
Conclusions
This article outlines a variety of factors which appear to underlie the association of aging with the risks of developing the sporadic form of PD, and analyses the actions and potential synergies of four agents which effectively manage these risks as judged by experimental and case history evidence. Although there are also evident distinctions to be drawn between underlying events in normal aging and PD (Darbin, 2012; Hindle, 2010; Kish et al., 1988; Kish et al., 1992; Zheng et al., 2010) , the result that the effective management of known specific risks to energy metabolism, mitochondrial functions, and gene expression associated with aging, can deliver an improved outcome in PD, emphasizes the links between these apparently different conditions.
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